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Single cord blood unit (CBU) predominance is usually established within the ﬁrst month after double
umbilical cord blood transplantation (UCBT). However, the kinetics of engraftment of the different leukocyte
subsets and the mechanism of graft predominance is largely unknown. To investigate whether a differential
engraftment might reveal a speciﬁc subset that could play a key role in the mechanism of graft predominance,
we studied early engraftment kinetics of different leukocyte subpopulations by ﬂow cytometry using human
monoclonal antigenespeciﬁc human leukocyte antigen antibodies, directed against mismatched human
leukocyte antigen-A or eB antigens between recipient and CBUs. Twenty-two patients, who had received
a double UCBT preceded by a reduced-intensity conditioning regimen, were evaluated at days þ11, þ18, þ25,
and þ32 posttransplantation. Single CBU predominance in the various leukocyte subsets was established
within 18 days posttransplantation. CD4þ T cells of the dominant CBU showed early peripheral blood
expansion. Moreover, chimerism in CD4þ and CD8þ T cell and natural killer cell subsets at day þ11 was
predictive of ultimate graft predominance. These ﬁndings show that engraftment kinetics of the various
leukocyte subsets vary considerably after double UCBT and may suggest an important role for CD4þ T cells in
a presumed alloreactive graft-versus-graft rejection.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION occur already early after transplantation [3,5,6,8]. Studies
Umbilical cord blood is an important alternative stem cell
source for children and adult patients in need of an alloge-
neic stem cell transplantation but lacking a matched sibling
or unrelated stem cell donor. However, the time to neutro-
phil recovery is delayed, and the incidence of graft failure is
higher after single umbilical cord blood transplantation
(UCBT) as compared with a matched unrelated stem cell
transplantation. This is especially found in adult patients
[1,2], which is generally attributed to the low number of
hematopoietic progenitor cells present in a single umbilical
cord blood unit (CBU). Double UCBT has been developed to
improve engraftment by administering higher numbers of
progenitor cells [3]. It has since been shown that double
UCBT is an appropriate alternative for patients lacking
a single adequately dosed CBU. Rates of sustained engraft-
ment of 85% to 100% are reported after double UCBT, both
after myeloablative and after nonmyeloablative conditioning
regimens [3-7]. Strikingly, sustained hematopoiesis is usually
derived from a single donor, and one of the CBUs disappears
or does not engraft at all.
Single-donor chimerism is generally documented within
3 months posttransplantation in most patients but mayedgments on page 273.
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12.09.022reported early predominance already at days 7 through 14
[8,9]. The mechanism of predominance of a particular unit,
however, has not yet been unraveled. Several explanations
have been brought forward, including immunological rejec-
tion and insufﬁcient cell viability. However, there is no
consistent correlation between dominance and the number
of nucleated cells, CD34þ hematopoietic precursor cells or
CD3þcells in the graft, degree of human leukocyte antigen
(HLA) mismatch, sex mismatch, ABO blood group, viability,
and order or route of infusion. Considering the early onset of
predominance, we set out to study early chimerism of
leukocyte subpopulations within the ﬁrst month after
double UCBT addressing the question of whether a differen-
tial engraftment pattern of leukocyte subsets might occur
and might play a role in graft predominance. By virtue of our
human monoclonal antibodies directed against HLA-A and
HLA-B antigens (HLA mAbs), leukocyte subsets were moni-
tored by ﬂow cytometry in patients receiving double UCBT
that were characterized by one or more mismatches in
HLA-A or HLA-B antigens between recipient and CBUs. It is
shown that graft predominance is an early and irreversible
phenomenon that occurs ﬁrst in both CD4þ T cells and
natural killer (NK) cells.
DESIGN AND METHODS
Patients
We selected a subgroup of patients who had undergone transplantation
according to our national multicenter, double UCBT trial protocol. ThisTransplantation.
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plantation in which, based on the presence of HLA mismatches between the
recipient and CBUs, the different parties could be distinguished with the use
of corresponding HLA mAbs. Eighteen patients had been enrolled in
a prospective phase II double UCBT trial protocol (clinicaltrials.gov identi-
ﬁer: NTR1573). Four additional patients had undergone transplantation in
a pilot study preceding the previously mentioned protocol with similar
eligibility criteria, conditioning regimen, and transplantation procedures. All
patients received a double UCBT between December 2007 and August 2011.
All patients gave written informed consent for the double UCBT procedure.
The trial protocol was approved by the Dutch Central Committee on
Research Involving Human Subjects.
Patients were eligible for double UCBT if they met the following criteria:
1. A diagnosis of a high-risk hematological malignancy (as deﬁned by
acute myeloid leukemia [AML] with monosomal karyotype, complex
karyotype, or EVI1 expression in ﬁrst complete remission; relapse
AML/myelodysplastic syndrome in the second or subsequent complete
remission; AML/myelodysplastic syndrome in ﬁrst complete remission
in patients aged 61 to 65 years inclusive; acute lymphoblastic leukemia
with t(9;22), t(4;11), t(1;19) or with high white blood cell count at
diagnosis in ﬁrst complete remission; relapse acute lymphoblastic
leukemia in second or subsequent complete remission; chronic
myeloid leukemia in the second chronic phase after treatment for
acceleration phase or blast crisis; lymphocytoplasmacytoid lymphoma,
follicular non-Hodgkin lymphoma, or chronic lymphocytic leukemia
[CLL], responsive disease after at least third-line chemotherapy, or
a [very] severe aplastic anemia) relapsing after or failing immuno-
suppressive therapy meeting the criteria for a matched unrelated
donor stem cell transplantation
2. Lacking a matched unrelated donor
3. Aged 18 to 65 years inclusiveCBU Selection
CBU selection was based on total nucleated cell (TNC) dose and HLA
match. The required minimum TNC dose was determined at 1.5  107/kg
recipient body weight for each individual CBU and at 4.0  107/kg for both
CBUs combined. CBUmatching was based on antigen level for HLA-A and -B
antigens and allele level for HLA-DRB1. The minimal match grade required
was a 4/6 match both between individual CBUs and recipient and between
CBUs. In all recipients, the presence of CBU-directed anti-HLA-A and -B
antibodies was excluded.
Transplantation Procedures
All patients received a nonmyeloablative conditioning regimen con-
sisting of cyclophosphamide (60 mg/kg) on day 7, ﬂudarabine (40 mg/m2)
on days 6 to 3, and total body irradiation (TBI, 2 Gy) on days 2 and 1.
Graft-versus-host disease prophylaxis consisted of cyclosporin A, twice
daily, from day5 for at least 3 months and mycophenolate mofetil, 3 times
a day from day 0 until dayþ30. Patients were hospitalized in laminar airﬂow
rooms until neutrophil counts had reached .2  109/L on 2 consecutive days.
Beginning day 7 until neutrophil recovery, antibacterial (ciproﬂoxacin)
and antifungal (ﬂuconazole or voriconazole) prophylaxis was given. From
day 0 until day þ15, streptococcal prophylaxis was added. Also, from day 0,
antiviral prophylaxis (valaciclovir) was given. Prophylaxis for Pneumocystis
jirovecii was started (trimethoprim-sulfamethoxazole) after neutrophil
recovery.
CBUs were infused with at least a 2-hour time interval in between. CBUs
were washed before infusion if the prefreeze red blood cell count exceeded
.15  1012 per bag for major ABO-incompatible products or .3  1012 per
bag for all other CBUs. In all other cases, CBUs were infused immediately
after a direct-thaw procedure at the bedside. A small aliquot of 7-amino-
actinomycin D was used to determine the number and viability of infused
CD34þcells, T cells, B cells, and NK cells.
Engraftment was deﬁned as neutrophil recovery (ANC .5109/L for at
least 2 consecutive days) in association with donor hematopoiesis >10% in
bone marrow. Complete donor chimerism was deﬁned as >95% donor
hematopoiesis (single or both donors) and <5% recipient hematopoiesis in
bone marrow; mixed chimerism was deﬁned as 10% to 95% donor hema-
topoiesis and >5% recipient hematopoiesis in bone marrow. Primary graft
failure was deﬁned as a persistent pancytopenia and marrow hypoplasia
with donor hematopoiesis<10% in bonemarrow. Chimerism analysis, based
on quantitative ampliﬁcation of informative short tandem repeat (STR)
regions by polymerase chain reaction (PCR) [10], was performed on fresh
unseparated peripheral blood cells, peripheral blood T cells, and unsepa-
rated bone marrow at day þ32.Posttransplantation Analysis of Early Chimerism in Leukocyte
Subpopulations
First, we assessed whether we would be able to distinguish leukocytes
derived from the different origins (recipient and CBUs) in each patient,
dependent on both the presence of HLA mismatches between recipient and
CBUs and the availability of appropriate HLA mAbs. For this purpose, we
performed ﬂow cytometry on both pretransplantation recipient peripheral
blood and individual CBUs. CBU samples were taken directly after thawing
of the graft. Posttransplantation ﬂow cytometry was performed at
days þ11, þ18, þ25, and þ32 if at least 1 CBU could be distinguished from
both other parties. In addition to ﬂow cytometry, chimerism analysis on
DNA was performed retrospectively on cryopreserved samples to compare
the results of ﬂow cytometry with the results of PCR.HLA AntigeneSpeciﬁc Monoclonal Antibodies
HLA-antibody producing hybridomas were generated as described
previously [11]. Selected anti-HLA-A and anti-HLA-B mAb-producing
hybridomas were cultured, and human immunoglobulin from the super-
natant was puriﬁed, concentrated, and directly labeled with Alexa-488
ﬂuorochrome (Molecular Probes/Invitrogen, Breda, The Netherlands) or
with PE-Dy 647 (Sanquin Reagents, Sanquin, Amsterdam, The Netherlands)
[12].Flow Cytometry
Peripheral blood was preincubated for 10 minutes in the dark with
human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany)
to prevent nonspeciﬁc binding of the HLAmAbs. Next, samples were stained
with the ﬂuorochrome-labeled HLA mAbs and anti-CD45 (PC7) (Beckman
Coulter, Fullerton, CA). Lineage-speciﬁc monoclonal antibodies (anti-CD3
[ECD], anti-CD4, anti-CD8, anti-CD19, anti-CD16/56, anti-CD14, anti-CD33
[PE]; Beckman Coulter) were added to identify leukocyte subsets. After
incubation for 20 minutes in the dark, red blood cells were lysed by adding
1 mL of 1:10 diluted lysis buffer (IOTest, Beckman Coulter) per tube and
incubation for 10 minutes in the dark. Next, samples were placed on ice and
ﬂow count ﬂuorospheres (Flow-Count Fluorospheres, Beckman Coulter)
were added to allow quantitative analysis. Cells were analyzed on
a Cytomics FC 500MPL ﬂowcytometer (Beckman Coulter). Gateswere set on
T cells (CD45þ/CD3þCD4þ/low side scatter [SS] and CD45þ/CD3þ/CD8þ
low SS), B cells (CD45þ/CD3-/CD19þ low SS), NK cells (CD3-/CD16/56þ
low SS), monocytes (CD45þ/CD14þ intermediate SS), and granulocytes
(CD45þ/CD33þ/intermediate to high SS).
Results of pretransplantation ﬂow cytometry were used to set the gates
for discrimination between the different origins of leukocyte subsets. All
samples were prepared and measured in duplicate. Data were calculated
using CXP analysis software (Beckman Coulter). Mean values of absolute cell
counts and percentages were calculated from duplicate results. For each
measurement, amaximumdeviation of 10% from themean of both duplicate
measurements was allowed. Samples were excluded from analysis if less
than 25 events per leukocyte subset were counted [13].RESULTS
Patients and CBUs
Twenty-two (of 48) patients were eligible for early
chimerism studies by ﬂow cytometry (Table 1), as a result of
available HLA mAbs, discriminating between recipient and
CBUs. Acute leukemia was the most common diagnosis
(AML, 12 patients; acute lymphoblastic leukemia, 5 patients
in ﬁrst or subsequent remission) followed by CLL (3 patients),
(very) severe aplastic anemia (1 patient), and chronic
myeloid leukemia in the second chronic phase (1 patient).
The median age was 53 years (range, 20-64), and the median
weight was 77 kg (range, 53-115). Nine patients received 2
4/6 matched CBUs, and 10 patients received 1 4/6 matched
CBU in combination with a 5/6 matched CBU; 2 patients
received 2 5/6 matched CBUs, and 2 patients a 6/6 matched
CBU in combination with a 5/6 matched CBU. None of the
CBU combinations exhibited more than 2 mismatches
(Table 1). Twenty-six (of 48) patients were not eligible for
early chimerism studies due to lack of HLA-A and/or -B
mismatches (n ¼ 8) or lack of HLA mAbs with speciﬁcity for
mismatches present (n ¼ 18).
Table 1
HLA I Typing of Patients and CBUs
Patient Recipient Predominant CBU Nonengrafting CBU
HLA-A* HLA-B* HLA-DRB1 HLA-A* HLA-B* HLA-DRB1 HLA-A* HLA-B* HLA-DRB1
1 1, 68 7, 51 07:01, 13:01 1, 68 7, 51 07:01, 13:01 29, 68 7, 51 07:01, 13:01
2 3, 32 27, 60 08:01, 13:01 2, 3 60, d 08:01, 13:01 3, 23 60, 61 08:01, 13:01
3 11, 68 27, 51 04:07, 15:01 11, 68 27, 44 04:07, 15:01 11, 68 27, 53 10:01, 15:01
4 2, 11 27, 41 07:01, 12:01 2, 11 7, 27 12:01, 15:05 2, 11 27, 44 07:01, 12:01
5 1, 2 51, 61 04:04, 14:54 1, 2 44, 51 07:01, 14:54 1, 2 51, 55 04:04, 14:54
6 2, 30 13, 52 07:01, 13:01 2, 30 13, 51 07:01, 13:01 2, 3 13, 60 07:01, 13:01
7 2, 32 37, 62 03:01, 10:01 2, 25 37, 62 10:01, 15:01 1, 2 37, 62 08:01, 10:01
8 1, 24 44, 62 01:01, 16:01 1, 24 35, 44 01:01, 16:01 1, 24 44, 62 01:01, 07:01
9 2, 11 44, 56 09:01, 16:01 2, 11 44, 60 04:04, 09:01 2, 11 44, 35 01:01, 09:01
10 2, 31 27, 40 01:03, 13:03 1, 2 27, 40 01:03, 04:01 2,d 27, 40 01:03, 11:01
11 30, 68 27, 51 13:02, 15:01 2, 30 18, 51 13:02, 15:01 24, 30 7, 51 13:02, 15:01
12 25, 31 49, 57 01:01, 08:01 11, 31 39, 49 01:01, 08:01 26, 31 49, 62 01:01, 08:01
13 31, 32 18, 57 07:01, 16:01 1, 31 18, 44 07:01, 16:01 30, 31 13, 18 07:01, 16:01
14 11, 68 27, 35 11:04, 13:01 11, 68 18, 35 11:04, 13:01 11, 32 27, 35 11:04, 13:01
15 2, 26 37, 39 07:01, 12:01 1, 2 27, 37 07:01, 12:01 2,d 37, 55 07:01, 12:01
16 26, 31 8, 38 03:01, 11:03 3, 26 8, 38 03:01, 04:02 26, 68 8, 38 03:01, 11:01
17 2, 3 7, 8 08:01, 10:01 2, 24 7, 51 08:01, 10:01 2, 25 7,d 08:01, 10:01
18 3, d 7, 44 04:01, 13:01 3, d 7, 44 04:01, 13:01 3,d 7, 35 04:01, 13:01
19 68, 80 52, 53 07:01, 13:02 11, 68 52, 53 04:03, 13:02 68, 80 52, 53 11:01, 13:02
20 23, 33 45, 57 07:01, 11:01 2, 23 45, 57 07:01, 11:01 23, 29 45, 57 03:01, 07:01
21 2, 74 58, 72 11:02, 13:02 2, 66 58, 72 13:01, 13:02 2, 74 51, 72 11:02, 13:02
22 3, 30 18, 51 11:01, 13:03 3, 32 27, 51 11:01, 13:03 2, 3 14, 51 11:01, 13:03
* HLA antigens as deducted from intermediate resolution HLA typing. HLA-A and -B antigens used for discrimination of CBUs and/or CBU(s) from recipient are
depicted in bold. HLA-DRB1 mismatches between predominant CBU and nonengrafting CBU are depicted in bold. Patients 2-5, 9, 11-17, 22: simultaneous
detection of both CBUs and recipient; patients 1, 6, 7, 18: detection of nonengrafting CBU only; patients 8, 10, 19-21: detection of predominant CBU only.
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No graft failures were observed in the 22 patients eligible
for early chimerism studies by HLA mAbs. Twenty-one
patients (95%) met the criteria for engraftment with
a median time to neutrophil recovery of 33 days (range, 11-
63). One patient died at day þ31 due to infectious compli-
cations with recovered neutrophil counts before routine
chimerism analysis by STR-PCR had been performed, but
ﬂow cytometry results showed single-donor chimerism at
day þ25. The median time to neutrophil recovery in patients
not eligible for ﬂow cytometry was 35 days (range, 15-47); at
day þ32 complete donor and mixed chimerism was estab-
lished in 21 of 26 and in 3 of 26 (1 patient not tested)
patients, respectively. Primary graft failure was observed in
one patient not eligible for early chimerism studies.
Chimerism by STR-PCR
Chimerism analysis by STR-PCR at day þ32 in bone
marrow and peripheral blood revealed complete single-
donor chimerism in 15 of 21 patients (71%). Mixed chimerism
was observed in 5 of 21 patients (24%) at day þ32. In 2 of
them (both with a diagnosis of CLL), 20% and 35% of recipient
hematopoiesis was present, respectively, in combination
with hematopoiesis derived from a single CBU. In these 2
patients, the numbers of infused viable CD34þ cells of the
predominant and nonengrafting CBUs were not different
from numbers received by other patients. In 2 other patients
withmixed chimerism (both with a diagnosis of AML), 90% of
hematopoiesis was derived from a single CBU. The ﬁfth
patient with mixed chimerism was diagnosed with early
relapse AML, resulting in 88% recipient hematopoiesis in
combination with 12% single-donor hematopoiesis.
Split chimerism (circulating T cells of recipient origin, noneT
cells of single-donor origin) was observed in 1 of 21 patients
(5%). Except for both CLL patients with mixed chimerism
and the patient with early relapsed AML, recipient hemato-
poiesis did not contribute to peripheral blood neutrophil
recovery.The precryopreserved TNCs and number of CD34þ cells as
well as the postthaw number of viable CD34þ cells, T, B, or
NK cells did not correlate with CBU predominance, nor did
the number of HLA mismatches and order of infusion
(Table 2). In addition, killer-cell immunoglobulin-like
receptor ligand mismatch in the direction of the predomi-
nant versus nonengrafting CBU did not correlate with graft
predominance (results not shown).
Early Chimerism Studies of Leukocyte Subpopulations by
Flow Cytometry
Simultaneous 3-donor-origin detection of leukocyte
subpopulations based onHLAdisparitieswas possible in 13 of
22 patients. In 9 patients, only 1 CBU (predominant, 5; non-
engrafting, 4) could be distinguished from the other sources
(Table 1). First, we evaluated early chimerism in individual
patients. Results of a representative patient are depicted in
Figures 1 and 2. At day þ11, both CBUs contributed to the
various leukocyte subpopulations, but a clear predominance
of the ultimately engrafting CBU existed already in most
subsets. At day þ18, the contribution of the nonengrafting
CBUwas negligible or absent, and peripheral blood cells were
almost exclusively derived from the engrafting CBU. That
pattern of engraftment, showing predominance of one
particular CBU as early as from day þ11 in most leukocyte
subpopulations and virtually complete disappearance of the
nonengrafting CBU as from day þ18 onward, was a general
phenomenon in all patients reaching single-donor chime-
rism at dayþ32. The nonengrafting CBU had vanished almost
completely at day þ11 in four patients. The contribution of
recipient cells at dayþ11 varied among the different patients
but was negligible thereafter (except for both CLL patients
with mixed chimerism and the patient with relapsed AML).
Next, we analyzed the pattern of disappearance of non-
engrafting CBUs, the engraftment kinetics of predominant
CBUs, and the presence of recipient cells to identify and
describe a general pattern. The patient with early relapsed
AML was excluded from the analyses of engraftment kinetics
Table 2
Graft Characteristics of Predominant Versus Nonengrafting CBU
Total (n ¼ 44) Predominant CBU Nonengrafting CBU
Dose Range n Dose Range n Dose Range n P Value*
TNC  107/kgy 2.6 1.5-5.2 2.5 1.5-5.2 2.8 1.5-4.6 .51
CD34þ cells  105/kgy 1.0 .11-4.4 1.1 .11-4.4 .9 .3-2.2 .14
Viable CD34þ cells  105/kgz .3 .05-1.1 .3 .05-1.0 .3 .11-1.1 .80
Viable CD3þ cells  105/kgz 4.1 .36-31.5 4.0 1.0-19.0 3.8 .36-31.5 .40
Viable CD19þ cells  105/kgz 9.5 3.8-19.3 10.8 3.0-18.5 8.6 3.8-21.5 1.0
Viable NK cells  105/kgz 8.5 .4-17.3 8.7 .6-17.3 8.5 2.7-16.7 .89
HLA mismatch 1.0
0/6 2 1 1
1/6 15 7 8
2/6 27 14 13
Order of infusion
First 11 11 1.0
TNC indicates total nucleated cell count; n, number of CBUs.
* Paired Student t-test, 2-sided.
y Median cell numbers precryopreservation.
z Median cell numbers after thawing (7-7-amino-actinomycinenegative cells).
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as persisting leukemia affected early chimerism. Results of all
predominant CBUs that could be distinguished (n¼ 18) were
combined. Similarly, results of nonengrafting CBUs (n ¼ 17)
were combined. The presence of recipient cells could be
analyzed in 13 patients.
At least 75% of samples contained a sufﬁcient number of
events in the respective subsets to analyze CD3þ lympho-
cytes, CD4þ lymphocytes, NK cells, monocytes, and gran-
ulocytes. However, 69% and 83% of measurements
concerning the CD8þ and B lymphocyte subsets, respec-
tively, had to be excluded because of the very low numbers of
events (Table 3). The origin of various leukocyte subsets in
peripheral blood was calculated and expressed as median
percentages (and range) for each party (nonengrafting CBU,
predominant CBU, and recipient) at the different time points
(Table 3). Furthermore, median absolute cell counts of each
contributing party were calculated (Figure 3).
CBU Dominance
As from day þ11 onward, the contribution of the
predominant CBU in both the CD4þ and CD8þ Tcell fractions
was larger than 50% (range, 59.3-100), increasing to more
than 90% (range, 78.4-100) at day þ18 in all but one patient.
Results of CD8þ Tcells could only be reliably determined in 5
patients at these time points. Predominance of the surviving
CBU evolved slower within the myeloid and NK cell pop-
ulations as compared with the pattern of T cell predomi-
nance. The contribution of the ultimate predominant CBU to
myeloid cells was less than 50% (range, 0-45.8) in most
recipients at day þ11, increasing to more than 50% (range,
62.7-99.6) at day þ18 in all but 1 recipient. B lymphocyte
counts were very low and could only be reliably determined
after day þ25. Most cells (>90%) in all subsets were derived
from the predominant CBU beyond day þ18 in all but 1
patient. The median absolute counts of CD4þ cells, NK cells,
and myeloid cells of the dominant CBU increased gradually
from day þ11 onward, whereas B lymphocyte counts and
CD8þ cells in blood showed no increase during the ﬁrst
month (Figure 3A). Of note, whereas CD8þ T cell recovery
severely lagged behind, a strong increase of CD4þ T cells was
observed, resulting in median values of, respectively, 40, 175,
and 240/mL (range, 20-610) at 1, 2, and 6 months
posttransplantation, which even exceeded CD4þ T cell
recovery in recipients of (adult) matched unrelated donor
grafts in our center (results not shown).Nonengrafting CBU
The contribution of both CD4þ and CD8þ T cells derived
from the nonengrafting CBU was less than 5% at day þ11 in
50% of patients, decreasing to less than 5% in all patients at
day þ18 (Table 3). The disappearance of the nonengrafting
CBU among NK cells and myeloid subsets was more pro-
tracted. B lymphocyte counts were very low throughout the
ﬁrst weeks posttransplantation and could only be reliably
determined in some patients. Finally, the contribution of the
nonengrafting CBU was less than 10% in all subsets from
day þ25 onward, with the exception of a persisting small
fraction of B cells. Collectively, the kinetic pattern of disap-
pearance turned out to be spearheaded by the CD4þ and, as
far as measurable, CD8þ T cell subsets, followed by NK and
myeloid cells. The absolute counts of the various subsets
derived from the nonengrafting CBU did not increase beyond
day þ11 in any patient and that CBU never contributed to
peripheral leukocyte recovery (Figure 3B), as a result of
which that unit was uniformly characterized as the “non-
engrafting” unit.Recipient Hematopoiesis
The contribution of recipient cells to the various
subsets had decreased to less than 1% in most patients at
day þ25, in the course of which recipient-derived CD4þ and
CD8þ T cells disappeared most rapidly with more protracted
disappearance of myeloid cells. Recipient hematopoiesis
never contributed to neutrophil recovery in any of the
patients reaching single-donor chimerism at day þ32
(Figure 3C).Early Prediction of CBU Predominance
The presence of engrafting and nonengrafting CBUs could
be monitored simultaneously in 13 patients. We questioned
whether or not predominance of one of the administered
CBUs in a particular subset at day þ11 would predict for
ultimate graft predominance. At day þ11 already, ultimate
predominance was reliably predicted by chimerism within
the CD4þ subset (10 of 10 assessable patients [100%]), CD8þ
subset (5 of 5 assessable patients [100%]), and NK cell subset
(10 of 11 patients [91%]), whereas B lymphocyte counts were
too low for analysis in most patients. In contrast, predomi-
nance of the ultimately engrafting CBU in monocytes and
granulocytes was observed in 7 of 11 (64%) and in 4 of 13
(31%) of patients, respectively.
Figure 1. Patient 9: Flow cytometry of (A) CD45þ cells and (B) CD4þ T cells at day þ 11 and day þ18 posttransplantation. Both CBUs and recipient are HLA-A2
positive. The predominant CBU is HLA-B60 positive, whereas the nonsustaining CBU is HLA-B35 positive (see Table 1). Samples were stained using anti-HLA-A2
(PE Dy 647) in combination with anti-HLA-B60 (Alexa-488) or anti-HLA-B35 (Alexa-488). The number of recipient cells was calculated as follows: number of
recipient cells ¼ total cell number  (HLA-B60  positive cells þ HLA-B35  positive cells).
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Flow cytometry results could be compared with PCR data
in 18 patients. Both tests at day þ32 corresponded in all
cases. The pattern of chimerism obtained by ﬂow cytometry
at days þ11, þ18, and þ25 in CD45þ cells corresponded
largely with the results of STR-PCR in unseparated peripheral
blood cells obtained retrospectively, with the exception of 2
patients in which the nonengrafting CBU, still detectable by
ﬂow cytometry, was not detected at dayþ11 by PCR (data not
shown).
DISCUSSION
Sustained hematopoiesis is usually derived from a single
donor after double UCBT. The kinetics and chimerism of
leukocyte subset recovery as well as the mechanism of graft
predominance, however, are largely unknown. In the present
study, we analyzed engraftment kinetics of leukocyte
subpopulations within the ﬁrst month after double UCBT.
Leukocyte subsets were monitored by ﬂow cytometry using
HLA mAbs, directed against mismatched HLA-A or -Bantigens between recipient and CBUs. It revealed that graft
predominance is a very fast and irreversible phenomenon,
occurring within the ﬁrst weeks posttransplantation.
Engraftment kinetics varied among the different leukocyte
subsets. The ﬁrst subsets showing predominance of the
engrafting CBU at day þ11 were CD4þ T cells, CD8þ T cells,
and NK cells, followed gradually by myeloid subsets of that
CBU. Reversal of early predominance was not observed in
this series. Cytotoxic CD8þ T cells could only be reliably
determined in some patients due to very low absolute CD8þ
T lymphocyte counts, which, in particular contrast to CD4þ T
cells and NK cells, did not increase during the ﬁrst month
posttransplantation. In addition, the proportion of the non-
engrafting CBU, although readily detectable early after
transplantation, rapidly decreased to less than 1% in most
recipients during the ﬁrst month posttransplantation, in
the course of which lymphoid cells disappeared faster
than myeloid cells. This ﬁnding of early graft predominance
is in line with previous studies, reporting dominant
engraftment of one of both CBUs within the ﬁrst month
Figure 2. Pt. no. 9: Early chimerism in leukocyte subpopulations. Contribution of CBU- and recipient derived cells to peripheral blood cells at day þ11, þ18, þ25 and
þ32 posttransplantation. Analysis of CD8þ Tcells was not possible due to the low number of events. CD4 Tcells: CD45þ/3þ/4þ/low SS T lymphocytes; NK cells: CD45þ/
3-/16/56þ/low SS cells; monocytes: CD45þ/14þ cells; granulocytes: CD45þ/33þmyeloid cells. predominant CBU; non-engrafting CBU; recipient; absolute cell count.
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myeloablative conditioning regimens [8,9,14].
Several mechanisms that might be responsible for graft
predominance have been explored. The content of TNC or
CD34þ cells, the number of granulocyte macrophage colony-
forming units, degree of donorerecipient HLA disparity, ABO
blood groupmatch, gendermatch, and order of infusion haveTable 3
Median percentages of circulating peripheral blood cells originating from non-eng




T-lymphocytes Non-engrafting 15 2.4 (0-26.6) 15
Predominant 15 85.7 (1.2-99.6) 16
Recipient 12 10.4 (0.4-94.2) 12
CD4+T-lymphocytes Non-engrafting 12 5.2 (0-42.3) 12
Predominant 12 88.1 (16.0-100) 13
Recipiënt 9 10.8 (0-54.1) 9
CD8+T-lymphocytes Non-engrafting 5 2.6 (0-22.4) 5
Predominant 5 96.1 (74.4-100) 5 1
Recipiënt 5 1.6 (0-23.2) 4
B-lymphocytes Non-engrafting 1 1.2 n.a 2
Predominant 0 n.a n.a. 1
Recipient 0 n.a n.a. 0
NK-cells Non-engrafting 15 13.9 (0-39.0) 16
Predominant 15 63.1 (35.7-98.5) 16
Recipiënt 11 18.0 (0-57.1) 12
Monocytes Non-engrafting 12 13.1 (0.4-40.5) 15
Predominant 14 61.3 (0.7-96.6) 16
Recipient 9 46.6 (4.5-84.0) 12
Granulocytes Non-engrafting 16 16.3 (0-48.8) 16
Predominant 16 15.6 (0-98.3) 17
Recipient 13 74.8 (1.7-100) 13
Non-engrafting CBU, predominant CBU and recipient cells were analyzed in 17, 18
n indicates number of evaluable patients; n.a., not applicable.not consistently been found predictive for survival or
disappearance in a certain CBU combination [3,6,15,16].
Single reports suggested a role for CD34þ viability [17] or the
content of aldehyde dehydrogenase bright cells [18]. An
association of higher CD3þ cell dose with CBU dominance
was reported by 2 separate groups [14,19]. Alloreactive graft-
versus-graft effects as an important underlying mechanismrafting CBU, predominant CBU and recipient







0.05 (0-10.4) 16 0.1 (0-5.2) 16 0.1 (0-7.4)
99.4 (0-100) 16 99.8 (0-100) 16 99.4 (2.3-100)
0.2 (0-100) 13 0.1 (0-95.9) 12 0.6 (0-96.8)
0.1 (0-1.5) 12 0 (0-8.7) 14 0.09 (0-2.2)
98.7 (32.7-100) 12 99.8 (47.0-100) 14 99.7 (2.9-100)
0.4 (0-7.7) 9 0 (0-1.7) 9 0.3 (0-3.1)
1.1 (0-4.1) 4 1.3 (0.6-4.5) 8 0.09 (0-4.9)
00 (78.5-100) 6 99.5 (57.1-100) 8 98.1 (0-100)
0.08 (0-29.2) 3 0.3 (0-41.1) 5 2.8 (0-95.1)
4.5 (2.1-6.9) 4 9.1 (0-19.4) 7 0 (0-6.7)
88.6 n.a 2 87.1 (80.6-93.6) 7 95.9 (83.6-100)
n.a. n.a. 2 3.2 (0-6.4) 4 2.0 (0-5.3)
0.4 (0-44.5) 15 0 (0-0.8) 16 0.07 (0-1.0)
96.8 (50.4-100) 16 98.3 (45.6-100) 17 98.8 (39.3-100)
3.9 (0-32.5) 12 1.4 (0-54.5) 12 1.0 (0-60.7)
0.9 (0-10.7) 14 0 (0-3.1) 14 0 (0-1.8)
94.1 (59.6-100) 15 99.6 (60.1-100) 15 99.8 (63.7-100)
2.3 (0-29.5) 12 0.3 (0-36.4) 11 0.2 (0-34.5)
2.3 (0-33.8) 15 0.2 (0-4.9) 15 0.2 (0-1.2)
89.5 (6.9-99.6) 15 98.8 (30.6-100) 15 99.6 (51.5-100)
4.7 (0-93.1) 12 0.5 (0-66.1) 11 0.07 (0-48.0)
and 13 patients, respectively.
Figure 3. Median absolute cell numbers of CBUs and recipient. (A) Predominant CBU, (B) nonengrafting CBU, and (C) recipient. CD4: CD45þ/3þ/4þ
T lymphocytes (reference values, .49-1.54  109/L); CD8: CD45þ/3þ/8þ T lymphocytes (reference values, .49-1.54 109/L); CD19: CD45þ/3-/19þ B cells (reference
values, .130-.63  109/L); CD56: CD45þ/3-/16/56þ NK cells (reference values, .1-.67  109/L); CD14: CD45þ/14þ monocytes; CD33: CD45þ/33þ myeloid cells.
J.A.E. Somers et al. / Biol Blood Marrow Transplant 19 (2013) 266e273272were strongly suggested by Gutman et al. [20], who identi-
ﬁed alloreactive interferon gesecreting CD8þ T cells (14 to
28 days after double UCBT) from the dominant CBU upon
stimulation with the nonsustaining CBU; Moretta et al. [21]
reported the presence of a cytotoxic CBU versus CBU effect
in a 2-way mixed-lymphocyte culture experiment also sup-
porting an immunologically mediated mechanism of graft
predominance. Moreover, the higher incidence of mixed
donoredonor (double) chimerism after anti-thymocyte
globulin veriﬁedecontaining conditioning regimens [22]
would also be compatible with an immunological mecha-
nism involved in induction of rapid single chimerism after
double UCBT. The administration of antithymocyte globulin
shortly before CBU infusion might result in a depletion of T
and NK cells in both grafts, which prevents the development
of alloreactive graft-versus-graft reactions.
Our observation of early Tcell chimerism of the ultimately
engrafting CBU is in line with data of Newell et al. [23], who
reported a highly predictive impact of CD3þ T cell chimerism
at day þ7 after transplantation. In addition, our observation
that CD4þ, CD8þ, and NK cell predominance always
preceded hematopoietic predominance supports an
immune-mediated mechanism underlying ultimate graft
predominance, involving either T cells, NK cells, or a combi-
nation. Apart from a relative increase of CD4þ T cells, we also
observed an increase in absolute numbers of CD4þ T cells
compatible with peripheral expansion as reported before
[24]. The early expansion of peripheral blood CD4þ T cells
accompanied with persistent low numbers of CD8þ T cells
might suggest a dominant role for CD4þ T cells. Although
CBU-derived T cells are thought to be naïve, it has been
shown that the T cells present in cord blood grafts are
immunologically potent [25,26] and may contribute to the
development of antigen-speciﬁc T cell responses in children
shortly after UCBT [24,27]. Therefore, we speculate that CD4
T cells of the predominant CBU might elicit a direct CD4þ
T cell response directed against mismatched HLA class IImolecules of the ultimate nonengrafting CBU cells as earlier
described in the matched unrelated transplantation setting
[28,29].
In our study, NK cells of the ultimate engrafting CBU
recovered rapidly to numbers within reference values within
the ﬁrst month posttransplantation. In general, NK cells,
regardless of stem cell source, are the ﬁrst leukocyte subset
reaching normal values [30], and NK cell expansion might
represent a nonspeciﬁc phenomenon. Although alloreactive
NK cells can be functionally competent at this early time
point [31], Tarek et al. could not demonstrate an association
of killer-cell immunoglobulin-like receptor mismatch with
CBU predominance in a large series of 83 patients [32].
One of the major advantages of nonmyeloablative
conditioning regimens is a restricted period of neutropenia,
due to mild myelosuppression leading to a gradual disap-
pearance of recipient neutrophils [33-35]. Various non-
myeloablative regimens are applied in cord blood
transplantation [4-6,36,37]. Brunstein et al. [38] reported
a median time to neutrophil recovery of 9 days after double
UCBT preceded by a cyclophosphamide/ﬂudarabine/TBI 2 Gy
regimen [38]. In the present study, neutrophil recovery was
established in all patients. However, the time to neutrophil
recovery was 33 days, with a rapid onset of neutropenia
(<.05  109/L), after a conditioning regimen containing
reduced-intensity cyclophosphamide and reduced-intensity
TBI. Furthermore, only the engrafting CBU contributed to
neutrophil recovery in our study. That observation differs
from other reports, in which either recipient hematopoiesis
[6,14,17] or the nonengrafting CBU [6] transiently contrib-
uted to neutrophil recovery. The dose of TBI (2  2 Gy) may
have especially contributed to the early onset of the neu-
tropenia, because that regimen is more intensiﬁed as
compared with the regimen of 2 Gy only, as developed in
Minneapolis [6]. Moreover according to institutional policy,
none of our patients received granulocyte colony-
stimulating factor, which is in contrast to most centers in
J.A.E. Somers et al. / Biol Blood Marrow Transplant 19 (2013) 266e273 273the United States using cord blood stem cells for allogeneic
transplantation [3-7]. Given the rapid rejection of 1 of 2 CBUs
administered, that same immunological mechanism might
be responsible for alloreactivity toward recipient hemato-
poiesis, contributing to a relatively rapid elimination of
residual recipient leukocytes as well [39].
To our knowledge, this is the ﬁrst study addressing
detailed engraftment kinetics in leukocyte subsets after
double UCBT. We demonstrated that graft predominance is
established within 11 days in all double UCBT recipients
reaching single-donor chimerism within 1 month post-
transplantation. The preferential early outgrowth of both
CD4 lymphocytes and their predictive power for ultimate
graft predominance may argue for a pivotal role of CD4
lymphocytes in an underlying immunological graft-versus-
graft reaction. Further functional studies to understanding
graft predominance should focus on the ﬁrst weeks post-
transplantation.
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